Skip to content

NMN for Frailty: What the Evidence Actually Shows

Category: musculoskeletal | ICD-10: R54 | Evidence tier: preliminary-human

What is Frailty?

Frailty is a syndrome of reduced physiological reserve in older adults, marked by exhaustion, slow gait, weak grip and unintentional weight loss. It predicts hospitalisation and mortality.

NMN relevance: the published evidence

Igarashi 2022 in older Japanese men touches frailty-adjacent endpoints (gait speed, grip) and reported modest gains at 250 mg/day. No trial has used a formal frailty index as the primary outcome. Exercise plus protein remains first-line.

Questions to ask before supplementing

250 mg/day per Igarashi 2022 in similar populations.

Contraindications and red flags

Comprehensive geriatric assessment should precede supplement use.

Bottom line for Malaysian patients

NMN is not registered with NPRA as a treatment for any specific condition; it is sold as a general health supplement. If you have frailty, use this page as a question list for a registered medical practitioner before adding NMN to existing therapy. Read our safety guide for full red-flag context.

Related conditions

Cited references